SEC EDGAR · Amended filing
HALO: amended insider filing
An amended ownership report was filed. Read the original and amendment before comparing transactions.
Follow HALO- Became public
- Oct 8, 2026, 7:55 PM EDT
- Event / period date
- May 5, 2026
- Collected
- Nov 8, 2026, 1:26 AM EST
Why this is connected
This filing identifies HALOZYME THERAPEUTICS, INC. as the issuer of the security. The company's SEC identifier connects it to HALO.
Reported transactions
Connaughton Bernadette (Director)
Code P covers open-market and private purchases. Grants, option exercises, and tax withholding are excluded from purchase results. Read the source footnotes for ownership and pricing details.
Source evidence
Read the source excerpt or record
<?xml version="1.0"?>
<ownershipDocument>
<schemaVersion>X0609</schemaVersion>
<documentType>4/A</documentType>
<periodOfReport>2026-05-05</periodOfReport>
<dateOfOriginalSubmission>2026-05-07</dateOfOriginalSubmission>
<notSubjectToSection16>0</notSubjectToSection16>
<issuer>
<issuerCik>0001159036</issuerCik>
<issuerName>HALOZYME THERAPEUTICS, INC.</issuerName>
<issuerTradingSymbol>HALO</issuerTradingSymbol>
<issuerForeignTradingSymbol></issuerForeignTradingSymbol>
</issuer>
<reportingOwner>
<reportingOwnerId>
<rptOwnerCik>0001662521</rptOwnerCik>
<rptOwnerName>Connaughton Bernadette</rptOwnerName>
</reportingOwnerId>
<reportingOwnerAddress>
<rptOwnerNonUSAddressFlag>false</rptOwnerNonUSAddressFlag>
<rptOwnerStreet1>C/O HALOZYME THERAPEUTICS, INC.</rptOwnerStreet1>
<rptOwnerStreet2>12390 EL CAMINO REAL</rptOwnerStreet2>
<rptOwnerCity>SAN DIEGO</rptOwnerCity>
<rptOwnerState>CA</rptOwnerState>
<rptOwnerZipCode>92130</rptOwnerZipCode>
<rptOwnerStateDescription></rptOwnerStateDescription>
</reportingOwnerAddress>
<reportingOwnerRelationship>
<isDirector>1</isDirector>
<isOfficer>0</isOfficer>
<isTenPercentOwner>0</isTenPercentOwner>
<isOther>0</isOther>
</reportingOwnerRelationship>
</reportingOwner>
<aff10b5One>0</aff10b5One>
<nonDerivativeTable>
<nonDerivativeTransaction>
<securityTitle>
<value>Common Stock</value>
</securityTitle>
<transactionDate>
<value>2026-05-05</value>
</transactionDate>
<transactionCoding>
<transactionFormType>4</transactionFormType>
<transactionCode>A</transactionCode>
<equitySwapInvolved>0</equitySwapInvolved>
</transactionCoding>
<transactionAmounts>
<transactionShares>
<value>3796</value>
<footnoteId id="F1"/>
<footnoteId id="F2"/>
</transactionShares>
<transactionPricePerShare>
<value>0</value>
</transactionPricePerShare>
<transactionAcquiredDisposedCode>
<value>A</value>
</transactionAcquiredDisposedCode>
</transactionAmounts>
<postTransactionAmounts>
<sharesOwnedFollowingTransaction>
<value>42294</value>
<footnoteId id="F2"/>
</sharesOwnedFollowingTransaction>
</postTransactionAmounts>
<ownershipNature>
<directOrIndirectOwnership>
<value>D</value>
</directOrIndirectOwnership>
</ownershipNature>
</nonDerivativeTransaction>
</nonDerivativeTable>
<derivativeTable></derivativeTable>
<footnotes>
<footnote id="F1">Represents annual restricted stock unit ("RSU") grant under the Issuer's director compensation program. Each RSU represents the right to receive one share of common stock of the Issuer. This grant will vest in full on the earlier of (i) May 5, 2027 and (ii) the date of the Issuer's next annual meeting of stockholders.</footnote>
<footnote id="F2">This Form 4/A amends the Form 4 filed on May 7, 2026 solely to correct the number of RSUs acquired and the amount of securities beneficially owned following the reported transaction. The original filing reported 6,796 RSUs acquired. The correct number of RSUs acquired was 3,796. As a result, the amount of securities beneficially owned following the transaction has been revised accordingly.</footnote>
</footnotes>
<remarks></remarks>
<ownerSignature>
<signatureName>/s/ James R. Oehler, Attorney-in-Fact</signatureName>
<signatureDate>2026-10-08</signatureDate>
</ownerSignature>
</ownershipDocument>
Congressional trading in HALO
These disclosures provide context. Their presence does not establish a link between a trader and the event.
- Oct 12, 2026$1K–$15K
Rep. Gilbert Ray Cisneros, Jr. (D-CA-31)
Sold (partial) Halozyme Therapeutics HALO
$1K–$15K · Traded Sep 29, 2026 · disclosed Oct 12, 2026
- Apr 7, 2026$1K–$15K
Rep. Gilbert Ray Cisneros, Jr. (D-CA-31)
Bought Halozyme Therapeutics HALO
$1K–$15K · Traded Mar 9, 2026 · disclosed Apr 7, 2026
- Apr 7, 2025$1K–$15K
Rep. Gilbert Ray Cisneros, Jr. (D-CA-31)
Sold (partial) Halozyme Therapeutics HALO
$1K–$15K · Traded Mar 24, 2025 · disclosed Apr 7, 2025
- Oct 3, 2024$1K–$15K
Rep. Josh Gottheimer (D-NJ-5)
Sold (partial) Halozyme Therapeutics HALO
$1K–$15K · Traded Sep 9, 2024 · disclosed Oct 3, 2024 · Joint
- Aug 13, 2023$15K–$50K
Rep. Daniel S. Goldman (D-NY-10)
Sold Halozyme Therapeutics HALO
$15K–$50K · Traded Jul 12, 2023 · disclosed Aug 13, 2023
- Jan 13, 2023$1K–$15K
Rep. Josh Gottheimer (D-NJ-5)
Sold (partial) Halozyme Therapeutics HALO
$1K–$15K · Traded Dec 6, 2022 · disclosed Jan 13, 2023 · Joint
- Dec 8, 2017$500K–$1M
Sen. Mark R. Warner (D-VA)
Sold (full) Halozyme Therapeutics HALO
$500K–$1M · Traded Nov 6, 2017 · disclosed Dec 8, 2017
Original documents control. Public records can be amended, and company connections may require interpretation. Nothing here is investment advice.